Gilead adds Phase 3 support for Livdelzi in PBC

Gilead reported new Phase 3 IDEAL data for Livdelzi, its PPAR-delta agonist seladelpar, showing statistically significant composite ALP normalization versus placebo after 52 weeks in adults with primary biliary cholangitis. The June 2, 2026 announcement is notable less because Livdelzi is new, the drug won FDA accelerated approval in 2024, and more because IDEAL targeted a narrower, clinically relevant group: patients whose ALP was still above normal but below 1.67 times the upper limit of normal on UDCA, or who were intolerant to UDCA. Gilead said that group is common in practice but has been underrepresented in randomized trials. (gilead.com)

That context matters. FDA’s approval of Livdelzi was based on a prior 12-month randomized trial in 193 patients with PBC and inadequate response or intolerance to UDCA, with biochemical response and ALP normalization serving as key efficacy measures. The current US label still carries the standard accelerated-approval caveat: the indication was cleared based on a surrogate marker, ALP reduction, and improvement in survival or prevention of liver decompensation events hasn’t yet been demonstrated. FDA review documents also identify confirmatory work as part of the path to continued approval. (fda.gov)

In IDEAL, the primary endpoint was stricter than simple ALP reduction. Gilead defined it as a composite of ALP at or below the upper limit of normal plus at least a 15% decrease from baseline at Week 52. The trial enrolled 96 adults ages 18 to 75 in a double-blind, placebo-controlled design. Gilead said seladelpar achieved significantly more composite ALP normalization than placebo and that the safety profile was consistent with prior Livdelzi studies, with no new safety concerns identified. The company has not yet released a full peer-reviewed dataset in the materials reviewed here, but it said complete results will be presented at an upcoming medical congress and discussed with regulators. (gilead.com)

The broader seladelpar story has been building for several years. In earlier studies and regulatory materials, the drug showed improvements in liver biochemistry and itch, a major quality-of-life issue in PBC. Gilead has also been pushing long-term and subgroup analyses, including ASSURE data presented around EASL 2026, to argue that ALP normalization is durable and clinically meaningful. Recent literature supports that framing: a 2025 meta-analysis found a stronger ALP-normalization signal with seladelpar 10 mg, and a 2026 publication linked ALP normalization, particularly alongside low bilirubin, with better complication-free survival in PBC. Those analyses don’t prove causality on their own, but they reinforce why regulators and hepatology researchers are focusing on normalization rather than modest improvement. (link.springer.com)

Expert reaction in the announcement was supportive, if expectedly close to the program. Cynthia Levy, MD, of the University of Miami, said IDEAL “further strengthens support” for Livdelzi’s efficacy and safety profile and supports ALP normalization as an achievable goal in patients with ALP between 1 and 1.67 times ULN. Gilead’s Swati Tole, MD, MS, framed the data as part of a broader effort to address persistent unmet need in PBC as the field shifts toward ALP normalization as a treatment goal. Independent commentary reviewed here generally aligns with that direction, emphasizing that PBC management is moving toward earlier recognition of residual risk, even in patients who don’t meet older high-ALP thresholds. (gilead.com)

Why it matters: For veterinary readers, this is a human hepatology story, but it’s still relevant as a window into how surrogate biomarkers, confirmatory studies, and symptom burden shape modern chronic-disease drug development. IDEAL addresses an important gray zone: patients who look better on paper than classic nonresponders, but may still carry meaningful progression risk. FDA review materials describe PBC as a rare, progressive autoimmune cholestatic disease that can lead to cirrhosis, liver failure, and transplant, while symptoms such as pruritus can be substantial. The lesson for clinicians across species is familiar: “near normal” biomarkers may not be enough, and developers are increasingly being pushed to show that earlier biochemical control is both achievable and clinically relevant. (accessdata.fda.gov)

There’s also a regulatory angle. Livdelzi’s label was revised in January 2026 and continues to note liver-test monitoring, fracture risk considerations, and the recommendation to avoid use in patients with complete biliary obstruction or decompensated cirrhosis. That means even positive IDEAL data won’t erase the need for careful patient selection and follow-up. If Gilead can convert these findings into confirmatory evidence that satisfies regulators, the drug’s position in PBC treatment algorithms could strengthen further, especially as the field compares newer PPAR-based options. (accessdata.fda.gov)

What to watch: Watch for the full IDEAL dataset at a medical meeting or in a journal, any regulator-facing updates from Gilead after those discussions, and whether treatment guidance begins to treat ALP normalization, especially in the 1.0 to 1.67 times ULN range, as a more explicit escalation trigger in PBC care. (gilead.com)